Advertisement

Picture Campus Berlin-Buch GmbH CBB Location of Future Innovation 650x100px
Collaboration › Details

Tamer Group–CellPhenomics: Reverse Clinical Engineering, 202211– collab sale of RCE of ASC Oncology by Tamer Group in MENA region

 

Period Period 2022-11-01
Organisations Partner, 1st Tamer Group
  Partner, 2nd ASC Oncology GmbH
  Group CellPhenomics (incl. ASC Oncology) (Group)
Products Product Reverse Clinical Engineering® testing procedure
  Product 2 pharmacodiagnostic test (PDx)
     

ASC Oncology GmbH. (11/1/22). "Press Release: ASC Oncology Proudly Announces New Partnership with Tamer Group". Berlin.

Cancer does not stop at borders - and neither does an approach to personalized cancer therapy developed in Berlin. Reverse Clinical Engineering® is now available to oncologists and cancer patients in Saudi Arabia, the Middle East, and North Africa.


Across borders, cancer is one of those diseases that is unpredictable, malignant and, despite high research efforts, not yet conquered. About 19.3 million people worldwide are diagnosed with cancer every year, and at the same time the prescribed chemotherapy fails in about half of all cancer patients. It is therefore essential to make advances in personalized cancer treatment available to doctors and cancer patients around the globe as quickly as possible and in a responsible manner.

Therefore, the Berlin-based biotech company ASC Oncology GmbH ("ASC Oncology") thinks beyond borders and is committed to the international use of Reverse Clinical Engineering® test procedure. The possibility that patients and oncologists know, based on scientific data, which drug is likely to work for an individual patient before a drug therapy is started should become a matter of course worldwide.

As an important next step in this journey, ASC Oncology today proudly announces its strategic partnership with Tamer Group. Through their century-long history, associated healthcare experience and the Tamer Group's large network in the Kingdom of Saudi Arabia, the Middle East and North Africa, the Reverse Clinical Engineering® testing procedure will thus become accessible to many patients as an important approach to personalized cancer therapy.

Tumor researcher Dr. Christian Regenbrecht, co-developer of the Reverse Clinical Engineering® procedure, emphasizes the benefits of the new partnership for cancer patients and treating physicians: "For three years, we have been using the testing procedure to support oncologists and patients in optimally individualising cancer treatment. With Reverse Clinical Engineering®, we test different drug treatment options before starting therapy and thus find the therapy option that is
most likely to have an effect on the individual patient's tumor. Outside the patient's body and thus without side effects. This is a key step on the road to establishing personalized cancer therapy, which we are now taking together with the Tamer Group."

Reverse Clinical Engineering® enables oncologists to offer their patients effective therapy from the outset. Using a tissue sample of the patient's tumor taken during a biopsy or tumor surgery, 3D copies of the tumor, called organoids, are grown in the laboratory. In the next step, various cancer drugs are tested on these organoids to determine their effectiveness on the individual patient's tumor. In this way, on the one hand, a probably unsuccessful therapy can be prevented from unnecessarily burdening the cancer patient and, on the other hand, the chance of a therapeutic response can be significantly improved.


Who is ASC Oncology?

ASC Oncology was founded by nine leading scientists from the fields of expertise pathology, tumor biology, biochemistry, biotechnology and molecular biology in 2019 with the aim of addressing the most important challenge of modern oncology: Providing patients with the right therapy at the right time. In doing so, ASC Oncology scientists are stepping up to advance precision medicine internationally through the Reverse Clinical Engineering® procedure developed in Berlin to partner with oncologists to provide cancer patients with the best possible therapy from the start. Our goal is to provide better care to more patients than ever before in the history of oncology. ASC Oncology - Rethink Oncology.


You will find the detailed press kit as well as press photos for your reporting in the press section of the website www.asc-oncology.com/press.

If you have any questions, please do not hesitate to contact Melanie Alperstaedt at presse@asc-oncology.com or +49 30 235 9467 76. If you have any scientific questions or need an interview, she will be happy to arrange an expert interview with Dr. Christian Regenbrecht and other scientists from the ASC Oncology team.


ASC Oncology GmbH
Public Relations
Robert-Rössle-Str. 10
13125 Berlin
+49 30 235 9467 76
presse@asc-oncology.com

   
Record changed: 2022-11-01

Advertisement

Picture [iito] Männer Ballett 650x100px

More documents for Tamer Group


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group Biotech Showcase 2023 San Francisco 650x300px




» top